Sigrid Therapeutics has started the Shine clinical trial for SiPore21, a device designed to control diabetes and obesity.
SiPore technology is based on mesoporous silica particles (MSPs), a colloidal amorphous silicon dioxide matrix. It acts like a “molecular sieve” to physically prevent the interaction between digestive enzymes and food, thereby reducing food breakdown into basic absorbable units. The SiPore21 device, if cleared, will be registered as a Class IIb medical device.